{
    "clinical_study": {
        "@rank": "14962", 
        "arm_group": [
            {
                "arm_group_label": "group R0", 
                "arm_group_type": "No Intervention", 
                "description": "remifentanil Ce of 0 ng/ml"
            }, 
            {
                "arm_group_label": "group R0.5", 
                "arm_group_type": "Active Comparator", 
                "description": "remifentanil Ce of 0.5 ng/ml"
            }, 
            {
                "arm_group_label": "group R1.0", 
                "arm_group_type": "Active Comparator", 
                "description": "remifentanil Ce of 1.0 ng/ml"
            }, 
            {
                "arm_group_label": "group R1.5", 
                "arm_group_type": "Active Comparator", 
                "description": "remifentanil Ce of 1.5 ng/ml"
            }
        ], 
        "brief_summary": {
            "textblock": "This study was designed to determine the optimal dose of remifentanil that can prevent the\n      complications associated with the removal of LMA without delaying emergence."
        }, 
        "brief_title": "Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Respiratory Complication", 
        "detailed_description": {
            "textblock": "Patients were randomly assigned to one of four groups. All patients received a predetermined\n      effect-site concentrations (Ce) of remifentanil by target-controlled infusion (TCI)\n      according to their group assignments (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce\n      of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml) from\n      10 minutes before the end of surgery to LMA removal. Airway complications (airway\n      obstruction, desaturation, breath holding, and coughing), nausea, and vomiting were assessed\n      during the emergence phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  American Society of Anesthesiologists physical status 1 or 2\n\n          -  undergoing lower extremity surgery under general anesthesia\n\n        Exclusion Criteria:\n\n          -  suspected difficult airways\n\n          -  respiratory disease (chronic obstructive pulmonary disease, upper respiratory\n             infection)\n\n          -  body mass index > 30 kg/m2\n\n          -  allergies to the study drugs\n\n          -  a history of gastric reflux"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915108", 
            "org_study_id": "apsj1"
        }, 
        "intervention": {
            "arm_group_label": [
                "group R0.5", 
                "group R1.0", 
                "group R1.5"
            ], 
            "description": "All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).", 
            "intervention_name": "Remifentanil", 
            "intervention_type": "Drug", 
            "other_name": "remifentanil (ultiva)"
        }, 
        "intervention_browse": {
            "mesh_term": "Remifentanil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 2, 2013", 
        "number_of_arms": "4", 
        "official_title": "Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal During Emergence From Sevoflurane-remifentanil Anesthesia", 
        "overall_official": {
            "affiliation": "Department of Anesthesiology and Pain Medicine, College of medicine, Yeungnam University, Daemyung-Dong, Nam-Gu, Daegu, Republic of Korea", 
            "last_name": "sangjin park, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "All patients received a predetermined Ce of remifentanil by TCI according to their group assignments from 10 minutes before the end of surgery to LMA removal. Adverse events such as coughing, airway obstruction, breath-holding, desaturation, nausea and vomiting were evaluated from the end of surgery until arrival in the post-anesthetic care unit.", 
            "measure": "Number of patients with adverse events following LMA removal", 
            "safety_issue": "Yes", 
            "time_frame": "from the end of surgery until arrival in the post-anesthetic care unit, an expected average of 15 minutes."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915108"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yeungnam University College of Medicine", 
            "investigator_full_name": "Sangjin Park", 
            "investigator_title": "assistant professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Yeungnam University College of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sangjin Park", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}